An alternate route for adeno-associated virus (AAV) entry independent of AAV receptor

Journal of Virology

Volumn 92, Issue 7, 2018, Pages

  Dudek, Amanda M ^a,b,e   Pillay, Sirika ^c   Puschnik, Andreas S ^c   Nagamine, Claude M ^c   Cheng, Fang ^d   Qiu, Jianming ^d   Carette, Jan E ^c   Vandenberghe, Luk H ^a,b,e,f  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD UNIVERSITY   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

AAV; Adeno associated virus; Attachment; Gene therapy; Vector; Viral entry; Viral gene transfer; Virus; Virus receptor

Indexed keywords

ADENO ASSOCIATED VIRUS RECEPTOR; UNCLASSIFIED DRUG; VIRUS RECEPTOR; CELL SURFACE RECEPTOR; KIAA0319L PROTEIN, MOUSE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ARTICLE; CELL ADHESION; CELL LYSATE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MOLECULAR EVOLUTION; MOLECULAR PHYLOGENY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEROTYPE; SIGNAL TRANSDUCTION; VIRUS CAPSID; VIRUS ENTRY; ANIMAL; CELL LINE; DEPENDOPARVOVIRUS; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; CAPSID; CELL LINE; DEPENDOVIRUS; GENETIC VECTORS; MICE; MICE, KNOCKOUT; RECEPTORS, CELL SURFACE; TRANSDUCTION, GENETIC; VIRUS INTERNALIZATION;

EID: 85043790566     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02213-17     Document Type: Article

References (57)

1. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365:2357-2365. https://doi.org/10.1056/ NEJMoa1108046
2. Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. 2014. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371:1994-2004. https://doi.org/10.1056/NEJMoa1407309
3. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross C, Aronica E, High KA, Levi MM, Hayden MR, Kastelein JJ, Kuivenhoven JA. 2008. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipasedeficient patients. Arterioscler Thromb Vasc Biol 28:2303-2304. https:// doi.org/10.1161/ATVBAHA.108.175620
4. Gaudet D, de Wal J, Tremblay K, Dery S, van Deventer S, Freidig A, Brisson D, Methot J. 2010. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler Suppl 11:55-60. https://doi.org/10.1016/j.atherosclerosissup.2010.03.004
5. Carpentier AC, Frisch F, Labbe SM, Gagnon R, de Wal J, Greentree S, Petry H, Twisk J, Brisson D, Gaudet D. 2012. Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. J Clin Endocrinol Metab 97:1635-1644. https://doi.org/10.1210/jc.2011-3002
6. Benkhelifa-Ziyyat S, Besse A, Roda M, Duque S, Astord S, Carcenac R, Marais T, Barkats M. 2013. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 21:282-290. https://doi.org/10.1038/mt.2012.261
7. Nizzardo M, Simone C, Rizzo F, Salani S, Dametti S, Rinchetti P, Del Bo R, Foust K, Kaspar BK, Bresolin N, Comi GP, Corti S. 2015. Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. Sci Adv 1:e1500078. https://doi.org/10.1126/sciadv.1500078
8. Armbruster N, Lattanzi A, Jeavons M, Van Wittenberghe L, Gjata B, Marais T, Martin S, Vignaud A, Voit T, Mavilio F, Barkats M, Buj-Bello A. 2016. Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy. Mol Ther Methods Clin Dev 3:16060. https://doi.org/ 10.1038/mtm.2016.60
9. Maguire AM, High KA, Auricchio A, Wright JF, Pierce EA, Testa F, Mingozzi F, Bennicelli JL, Ying GS, Rossi S, Fulton A, Marshall KA, Banfi S, Chung DC, Morgan JI, Hauck B, Zelenaia O, Zhu X, Raffini L, Coppieters F, De Baere E, Shindler KS, Volpe NJ, Surace EM, Acerra C, Lyubarsky A, Redmond TM, Stone E, Sun J, McDonnell JW, Leroy BP, Simonelli F, Bennett J. 2009. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374:1597-1605. https://doi.org/10.1016/S0140-6736(09)61836-5
10. Cideciyan AV, Hauswirth WW, Aleman TS, Kaushal S, Schwartz SB, Boye SL, Windsor EA, Conlon TJ, Sumaroka A, Pang JJ, Roman AJ, Byrne BJ, Jacobson SG. 2009. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther 20:999-1004. https://doi.org/10.1089/hum.2009.086
11. Simonelli F, Maguire AM, Testa F, Pierce EA, Mingozzi F, Bennicelli JL, Rossi S, Marshall K, Banfi S, Surace EM, Sun J, Redmond TM, Zhu X, Shindler KS, Ying GS, Ziviello C, Acerra C, Wright JF, McDonnell JW, High KA, Bennett J, Auricchio A. 2010. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18:643-650. https://doi.org/10.1038/mt.2009.277
12. Bennett J, Ashtari M, Wellman J, Marshall KA, Cyckowski LL, Chung DC, McCague S, Pierce EA, Chen Y, Bennicelli JL, Zhu X, Ying GS, Sun J, Wright JF, Auricchio A, Simonelli F, Shindler KS, Mingozzi F, High KA, Maguire AM. 2012. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 4: 120ra15. https://doi.org/10.1126/scitranslmed.3002865
13. Ng R, Govindasamy L, Gurda BL, McKenna R, Kozyreva OG, Samulski RJ, Parent KN, Baker TS, Agbandje-McKenna M. 2010. Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol 84:12945-12957. https://doi.org/10.1128/JVI.01235-10
14. Wu Z, Miller E, Agbandje-McKenna M, Samulski RJ. 2006. Alpha2, 3 and alpha2, 6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol 80:9093-9103. https:// doi.org/10.1128/JVI.00895-06
15. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72:1438-1445
16. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. 2002. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76:791-801. https://doi.org/10.1128/JVI.76.2.791-801.2002
17. Kaludov N, Brown KE, Walters RW, Zabner J, Chiorini JA. 2001. Adenoassociated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol 75:6884-6893. https://doi.org/10.1128/JVI.75.15.6884-6893.2001
18. Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. 2011. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem 286:13532-13540. https://doi.org/10.1074/jbc.M110.210922
19. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. 1999. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5:71-77. https://doi.org/10.1038/4758
20. Kashiwakura Y, Tamayose K, Iwabuchi K, Hirai Y, Shimada T, Matsumoto K, Nakamura T, Watanabe M, Oshimi K, Daida H. 2005. Hepatocyte growth factor receptor is a coreceptor for adeno-associated virus type 2 infection. J Virol 79:609-614. https://doi.org/10.1128/JVI.79.1.609-614.2005
21. Akache B, Grimm D, Pandey K, Yant SR, Xu H, Kay MA. 2006. The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80:9831-9836. https://doi.org/10.1128/JVI.00878-06
22. Kurzeder C, Koppold B, Sauer G, Pabst S, Kreienberg R, Deissler H. 2007. CD9 promotes adeno-associated virus type 2 infection of mammary carcinoma cells with low cell surface expression of heparan sulphate proteoglycans. Int J Mol Med 19:325-333
23. Blackburn SD, Steadman RA, Johnson FB. 2006. Attachment of adenoassociated virus type 3H to fibroblast growth factor receptor 1. Arch Virol 151:617-623. https://doi.org/10.1007/s00705-005-0650-6
24. Ling C, Lu Y, Kalsi JK, Jayandharan GR, Li B, Ma W, Cheng B, Gee SW, McGoogan KE, Govindasamy L, Zhong L, Agbandje-McKenna M, Srivastava A. 2010. Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther 21: 1741-1747. https://doi.org/10.1089/hum.2010.075
25. Di Pasquale G, Davidson BL, Stein CS, Martins I, Scudiero D, Monks A, Chiorini JA. 2003. Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9:1306-1312. https://doi.org/10.1038/nm929
26. Weller ML, Amornphimoltham P, Schmidt M, Wilson PA, Gutkind JS, Chiorini JA. 2010. Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat Med 16:662-664. https://doi.org/ 10.1038/nm.2145
27. Xiao PJ, Samulski RJ. 2012. Cytoplasmic trafficking, endosomal escape, and perinuclear accumulation of adeno-associated virus type 2 particles are facilitated by microtubule network. J Virol 86:10462-10473. https:// doi.org/10.1128/JVI.00935-12
28. Uhrig S, Coutelle O, Wiehe T, Perabo L, Hallek M, Buning H. 2012. Successful target cell transduction of capsid-engineered rAAV vectors requires clathrin-dependent endocytosis. Gene Ther 19:210-218. https://doi.org/10.1038/gt.2011.78
29. Duan D, Li Q, Kao AW, Yue Y, Pessin JE, Engelhardt JF. 1999. Dynamin is required for recombinant adeno-associated virus type 2 infection. J Virol 73:10371-10376
30. Nonnenmacher M, Weber T. 2011. Adeno-associated virus 2 infection requires endocytosis through the CLIC/GEEC pathway. Cell Host Microbe 10:563-576. https://doi.org/10.1016/j.chom.2011.10.014
31. Girod A, Wobus CE, Zadori Z, Ried M, Leike K, Tijssen P, Kleinschmidt JA, Hallek M. 2002. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J Gen Virol 83:973-978. https://doi.org/10.1099/0022-1317-83-5-973
32. Nicolson SC, Samulski RJ. 2014. Recombinant adeno-associated virus utilizes host cell nuclear import machinery to enter the nucleus. J Virol 88:4132-4144. https://doi.org/10.1128/JVI.02660-13
33. Pillay S, Meyer NL, Puschnik AS, Davulcu O, Diep J, Ishikawa Y, Jae LT, Wosen JE, Nagamine CM, Chapman MS, Carette JE. 2016. An essential receptor for adeno-associated virus infection. Nature 530:108-112. https://doi.org/10.1038/nature16465
34. Pillay S, Zou W, Cheng F, Puschnik AS, Meyer NL, Ganaie SS, Deng X, Wosen JE, Davulcu O, Yan Z, Engelhardt JF, Brown KE, Chapman MS, Qiu J, Carette JE. 5 July 2017. AAV serotypes have distinctive interactions with domains of the cellular receptor AAVR. J Virol https://doi.org/10.1128/JVI.00391-17
35. Gao G, Alvira MR, Somanathan S, Lu Y, Vandenberghe LH, Rux JJ, Calcedo R, Sanmiguel J, Abbas Z, Wilson JM. 2003. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc Natl Acad Sci U S A 100:6081-6086. https://doi.org/10.1073/ pnas.0937739100
36. Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol 78:6381-6388. https://doi.org/10.1128/JVI.78.12.6381-6388.2004
37. Lin J, Calcedo R, Vandenberghe LH, Bell P, Somanathan S, Wilson JM. 2009. A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque. J Virol 83:12738-12750. https:// doi.org/10.1128/JVI.01441-09
38. Vandenberghe LH, Breous E, Nam HJ, Gao G, Xiao R, Sandhu A, Johnston J, Debyser Z, Agbandje-McKenna M, Wilson JM. 2009. Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther 16:1416-1428. https://doi.org/10.1038/gt.2009.101
39. Blacklow NR, Hoggan MD, Rowe WP. 1968. Serologic evidence for human infection with adenovirus-associated viruses. J Natl Cancer Inst 40:319-327
40. Chiorini JA, Yang L, Liu Y, Safer B, Kotin RM. 1997. Cloning of adenoassociated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 71:6823-6833
41. Zinn E, Pacouret S, Khaychuk V, Turunen HT, Carvalho LS, Andres-Mateos E, Shah S, Shelke R, Maurer AC, Plovie E, Xiao R, Vandenberghe LH. 2015. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep 12:1056-1068. https://doi.org/10.1016/j.celrep.2015.07.019
42. Dalkara D, Byrne LC, Klimczak RR, Visel M, Yin L, Merigan WH, Flannery JG, Schaffer DV. 2013. In vivo-directed evolution of a new adenoassociated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 5: 189ra76. https://doi.org/10.1126/scitranslmed.3005708
43. Cronin T, Vandenberghe LH, Hantz P, Juttner J, Reimann A, Kacso AE, Huckfeldt RM, Busskamp V, Kohler H, Lagali PS, Roska B, Bennett J. 2014. Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med 6:1175-1190. https://doi.org/10.15252/emmm.201404077
44. Hamilton B, Zabner J. 2017. An alternative route of infection for a novel AAV, abstr 507. Abstr 20th Annu Meet Am Soc Gene Cell Ther, Washington, DC, 10 to 13 May 2017
45. Bell CL, Vandenberghe LH, Bell P, Limberis MP, Gao GP, Van Vliet K, Agbandje-McKenna M, Wilson JM. 2011. The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest 121:2427-2435. https://doi.org/10.1172/JCI57367
46. Mizukami H, Young NS, Brown KE. 1996. Adeno-associated virus type 2 binds to a 150-kilodalton cell membrane glycoprotein. Virology 217: 124-130. https://doi.org/10.1006/viro.1996.0099
47. Summerford C, Samulski RJ. 2016. AAVR: a multi-serotype receptor for AAV. Mol Ther 24:663-666. https://doi.org/10.1038/mt.2016.49
48. Qiu J, Handa A, Kirby M, Brown KE. 2000. The interaction of heparin sulfate and adeno-associated virus 2. Virology 269:137-147. https://doi.org/10.1006/viro.2000.0205
49. Negishi A, Chen J, McCarty DM, Samulski RJ, Liu J, Superfine R. 2004. Analysis of the interaction between adeno-associated virus and heparan sulfate using atomic force microscopy. Glycobiology 14:969-977. https://doi.org/10.1093/glycob/cwh118
50. Zhang F, Aguilera J, Beaudet JM, Xie Q, Lerch TF, Davulcu O, Colon W, Chapman MS, Linhardt RJ. 2013. Characterization of interactions between heparin/glycosaminoglycan and adeno-associated virus. Biochemistry 52:6275-6285. https://doi.org/10.1021/bi4008676
51. Muller OJ, Leuchs B, Pleger ST, Grimm D, Franz WM, Katus HA, Kleinschmidt JA. 2006. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc Res 70:70-78. https://doi.org/10.1016/j.cardiores.2005.12.017
52. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 7:539. https://doi.org/10.1038/msb.2011.75
53. Goujon M, McWilliam H, Li W, Valentin F, Squizzato S, Paern J, Lopez R. 2010. A new bioinformatics analysis tools framework at EMBL-EBI. Nucleic Acids Res 38:W695-W699. https://doi.org/10.1093/nar/gkq313
54. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. 2010. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol 59: 307-321. https://doi.org/10.1093/sysbio/syq010
55. Lock M, Alvira M, Vandenberghe LH, Samanta A, Toelen J, Debyser Z, Wilson JM. 2010. Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale. Hum Gene Ther 21: 1259-1271. https://doi.org/10.1089/hum.2010.055
56. National Institutes of Health. 2015. Public Health Service policy on humane care and use of laboratory animals. Office of Laboratory Animal Welfare, National Institutes of Health, Bethesda, MD
57. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC